Researchers cut the power in leukemia stem cells
According to proof-of-concept research published in the most recent edition of the journal Cancer Cell, researchers from Canada's Princess Margaret Cancer Program have found a new and potentially valuable use for a drug recently approved for purposes other than cancer.
Their work shows that the antibiotic tigecycline, marketed as Tygacil and part of a new class of antibiotics known as glycycyclines, can actually target and destroy the body's leukemia stem cells by shutting down the energy production within the cell, without causing chaos in other stem cells.
One of the researchers, Dr. Aaron Schimmer, described it as causing a power outage in the leukemia stem cells while maintaining power in the rest of the grid.
The group was able to test several hundred different, unconventional drugs against leukemia stem cells to see if they had any anti-cancer effect in just a matter of days thanks to advances in technology.
Source: Medical News Today
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
